Alnylam Pharmaceuticals Trading Volume Drops 41.67% to $199 Million Ranking 472nd

On July 14, 2025, Alnylam Pharmaceuticals (ALNY) saw a trading volume of $199 million, marking a 41.67% decrease from the previous day. The stock ranked 472nd in terms of trading volume for the day, with a slight increase of 0.26% in its stock price.

Jefferies analyst Maury Raycroft maintained a Buy rating and a price target of $384.00 for Alnylam Pharmaceuticals. The analyst's comments highlighted the company's strong performance, particularly in the sales of Amvuttra, which has been a significant driver of the stock's positive outlook.

This reiteration of the Buy rating comes as a vote of confidence in Alnylam's future prospects, reinforcing the belief in the company's ability to continue delivering strong financial results and innovative products to the market.